Medical/Pharmaceuticals
Raziel and Fosun Pharma (by JuveStar an affiliate company of Fosun Pharma) Initiate Phase 3 Registration Trial in China for Submental Fat Reduction ("double chin")
REROVOT, Israel, March 4, 2025 /PRNewswire/ -- Raziel Therapeutics, a pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market, announces phase 3 study initiation inChina for the treatment of fat reduction in the submental area. Submental fat...
2025-03-04 09:00
2278
Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
MELBOURNE, Australia and INDIANAPOLIS, Ind., March 4, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) invites investors to join a webinar showcasing the Company's late-stage and next-generation radiotherapeutic candidates in urologic oncology. In ...
2025-03-04 05:58
2885
Frost & Sullivan Recognizes Cynerio for Advancing Healthcare Cybersecurity with Its NDR-H Solution to Combat Cyber Threats
Cynerio's NDR-H Solution enables deep packet inspection, comprehensive network traffic analysis with real-time threat detection and response, and proactive auto identification and analysis of connected devices. SAN ANTONIO, March 3, 2025 /PRNewswire/ -- Frost & Sullivan recently analyzed the hea...
2025-03-03 22:00
2389
Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept
* Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience * Financing led by Frazier Life Sciences with significant participation from Jeito Capital alongside o...
2025-03-03 22:00
3927
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
* First ever head-to-head comparison of gut microbiome changes associated with ibezapolstat (IBZ) to other anti-CDI antibiotics in a germ-free mouse model * Changes in alpha and beta microbiome diversities following IBZ treatment were less pronounced compared to those observed in vancomycin (VA...
2025-03-03 21:00
2087
DrFirst Recognized for Enabling Technology Leadership in Healthcare by Frost & Sullivan
Leading the Way in Healthcare Innovation Across the Medication Journey SAN ANTONIO, March 3, 2025 /PRNewswire/ -- DrFirst, a leading innovator in healthcare technology, has been honored with the prestigious Enabling Technology Leadership Award by Frost & Sullivan. This recognition highlights how...
2025-03-03 21:00
2011
The 91st CMEF to Unveil Latest Trends in Medical Device Industry
China is flourishing in the industry, boasting more than 34,000 medical device companies and leading advancements in AI technologies. SHANGHAI, March 3, 2025 /PRNewswire/ -- The 91st China International Medical Equipment Fair (CMEF), the world's premier medical device exhibition, is set to take ...
2025-03-03 14:41
4264
Sole Pharma - Launches in the Philippines to Meet Rising Demand for High-Quality Supplements
MANILA, Philippines, March 3, 2025 /PRNewswire/ -- In response to the growing demand for high-quality health supplements in the Philippines, Sole Pharma, as one of the leading Europeanpharmaceutical manufacturer, announces its expansion into the Southeast Asian market. Products are available onli...
2025-03-03 08:55
2877
Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma
SAN FRANCISCO and SUZHOU, China, March 3, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...
2025-03-03 08:00
5663
Pulnovo Medical Announces Closing of Nearly $100 Million Series C Financing
SHANGHAI, March 3, 2025 /PRNewswire/ -- Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), has announced the closing of nearly$100 million Series C financing. This round was co-led by Qiming Venture Partners and existing share...
2025-03-03 08:00
4835
Hospital Kuala Lumpur & Rare Disease Patient Organizations Nationwide Celebrate Rare Disease Day 2025
KUALA LUMPUR, Malaysia, March 1, 2025 /PRNewswire/ -- For the first time, Hospital Kuala Lumpur (HKL) is proudly hosting the annual Rare Disease Day 2025 celebration to raise awareness and advocate for individuals affected by rare diseases inMalaysia. This milestone event is organized by the Depa...
2025-03-01 22:30
5244
Everest Medicines to Hold Investor Calls with Updates on mRNA Therapeutic Vaccine Programs
SHANGHAI, Feb. 28, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines, today announced that it will hold investor...
2025-02-28 14:28
5430
EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements
PROVIDENCE, R.I., Feb. 27, 2025 /PRNewswire/ -- EpiVax, Inc. proudly announces the appointment ofGuilhem Richard as Chief Technology Officer. Dr. Richard joined EpiVax's immunoinformatics team in 2014 and spearheaded the development of a new computational platform for developing personalized, neo...
2025-02-27 22:05
3536
Metabolon Unveils New Multiomics Biomarker Discovery Functionality via its Industry-leading Integrated Bioinformatics Platform
Metabolon's expertise extends beyond metabolomics to include data insights and software solutions for multiomics research MORRISVILLE, N.C., Feb. 27, 2025 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, dia...
2025-02-27 22:00
2684
Nezha Craze Sweeps the City Wai Yuen Tong Proudly Sponsors Broadcast of "Nezha: The Demon Child Comes into the World" on Jade Channel
HONG KONG, Feb. 27, 2025 /PRNewswire/ -- Hong Kong's traditional Chinese medicine pioneer Wai Yuen Tong (0897.HK) announced its proud sponsorship of the TVB Jade Channel's broadcast of the film " Nezha: The Demon Child Comes into the World " (Nezha 1) onFebruary 28 at 8 PM. This film will provid...
2025-02-27 20:09
4465
WuXi Biologics Again Passed GMP Inspection by Japan PMDA
WUXI, China, Feb. 27, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has again passed the GMP inspection byJapan's Pharmaceuticals and Medical Devices Agency (PMDA) for it...
2025-02-27 16:30
3927
Clarivate Report Explores Opportunities for Innovation and Market Expansion in Latin America
New insights from Clarivate examine strategic partnerships, API production, and innovation in the region LONDON, Feb. 27, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) a leading global provider of transformative intelligence, has released a new white paper, How is Latin America Growing?, sheddi...
2025-02-27 16:00
2411
Alpro Foundation & Universiti Teknologi MARA: Addressing Malaysia's Pharmaceutical Waste
KUALA LUMPUR, Malaysia, Feb. 27, 2025 /PRNewswire/ -- Malaysia is facing a growing environmental and public health threat due to improper disposal of pharmaceutical waste. Research indicates that 67% of Malaysians discard expired medications incorrectly—either by flushing them down the toilet or ...
2025-02-27 15:19
3207
Revolutionizing All-on-X: Medit's Game-Changing Workflow Will Launch Soon
SEOUL, South Korea and NEWPORT BEACH, Calif., Feb. 27, 2025 /PRNewswire/ --
Medit (www.medit.com
2025-02-27 15:00
7095
First Patient Dosed in a Phase III Clinical Study of Anti-HER2 Biparatopic ADC JSKN003 for the Treatment of HER2-positive Breast Cancer
SUZHOU, China, Feb. 27, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-301) of anti-HER2 bip...
2025-02-27 14:06
4800
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 273 media titles]
2026-10-09 13:21Southeast Asia's China travel map is widening, Traveloka platform data shows
[Picked up by 263 media titles]
2026-10-05 11:51